SR34006 Compared to Placebo in Patients Who Have Completed 6 Months of Treatment for Symptomatic Pulmonary Embolism or Deep Vein Thrombosis
The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006
Sponsor: Sanofi
Listed as NCT00071279, this PHASE3 trial focuses on Deep Vein Thrombosis and Pulmonary Embolism and remains completed. Sponsored by Sanofi, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Nov 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Alexandria, United States , Alkmaar, Almere, Amersfoort, Amsterdam, Arnhem, Haarlem, Netherlands , Allentown, United States , Arhus, Braedstrup, Frederiksberg, Glostrup, Hillerod, Denmark , Auckland, New Zealand , Augusta, United States , Baltimore, United States , Barcelona, Madrid, Torrelavega, Xativa, Spain , Bay Pines, United States and 49 more locations